Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

ClinicalTrials.gov ID: NCT01068782

Public ClinicalTrials.gov record NCT01068782. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Non-Comparative Randomized Open-Label Study of Multiple Regimens of Single-Agent XL184 in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study was conducted in subjects with grade IV astrocytic tumors (a type of cancer that can occur in the brain or spinal cord) in first or second relapse.

Study identification

NCT ID: NCT01068782
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Exelixis; Industry
Enrollment: 19 participants

Conditions and interventions

Conditions

Astrocytic Tumors

Interventions

Cabozantinib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 2010 (Type not available)
Primary completion: May 2011 (Actual)
Completion: Oct 2013 (Actual)
Last update posted: Feb 25, 2026

2010 – 2013

United States locations

U.S. sites: 17
U.S. states: 12
U.S. cities: 15

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35294	—
Not listed	Encinitas	California	92024	—
Not listed	Pleasant Hill	California	94523	—
Not listed	Chicago	Illinois	60611	—
Not listed	Chicago	Illinois	60637	—
Not listed	Boston	Massachusetts	02115	—
Not listed	Detroit	Michigan	48202	—
Not listed	Minneapolis	Minnesota	55407	—
Not listed	Amherst	New York	14226	—
Not listed	Rochester	New York	14642	—
Not listed	Cleveland	Ohio	44195	—
Not listed	Hershey	Pennsylvania	17033	—
Not listed	Dallas	Texas	75246	—
Not listed	Dallas	Texas	75426	—
Not listed	San Antonio	Texas	78229	—
Not listed	Charlottesville	Virginia	22908	—
Not listed	Seattle	Washington	98122	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01068782, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 25, 2026 · Synced Oct 22, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01068782 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →